Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Cancers|November 13, 2013
Molecular targeted agents for gastric cancer: a step forward towards personalized therapyEsther Una Cidon, Sara G Ellis, Yasir Inam, et al.Future Oncology (London, England)|December 12, 2025
A retrospective chart review of UK patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumabTom Geldart, Lisa Pickering, Anand Sharma, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 15, 2016
Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLCEdurne Arriola, Matthew Wheater, Ian Galea, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2015
Clinical and biological effects of an agonist anti-CD40 antibody: a Cancer Research UK phase I studyPeter Johnson, Ruth Challis, Ferdousi Chowdhury, et al.British Journal of Cancer|December 5, 2024
Long term efficacy of first-line afatinib and the clinical utility of ctDNA monitoring in patients with suspected or confirmed EGFR mutant non-small cell lung cancer who were unsuitable for chemotherapySanjay Popat, Adam Januszewski, Mary O'Brien, et al.Lung Cancer (Amsterdam, Netherlands)|October 24, 2025
Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: An international multicentre cohort studyIgor Gomez-Randulfe, Federico Monaca, Ornella Cantale, et al.JCO Precision Oncology|March 21, 2024
Plasma Proteome-Based Test for First-Line Treatment Selection in Metastatic Non-Small Cell Lung CancerPetros Christopoulos, Michal Harel, Kimberly McGregor, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2022
Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)Johnathan K Joffe, Fay H Cafferty, Laura Murphy, et al.Pageof 1